# US 2012/0252827 A1 · Combination of therapy comprising zd6474 and a taxane

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252827 A1
- Document ID: US20120252827A1
- Status: Published application
- Kind: A1
- Application number: 13/290,730
- Filed: 2011-11-07
- Published: 2012-10-04
- Earliest claimed: 2001-11-08
- Inventors: Stephen Robert WEDGE
- Web page: https://patentgrep.com/patent/US20120252827A1

## CPC

- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, particularly a method for the treatment of a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with a taxane; to a pharmaceutical composition comprising ZD6474 and a taxane; to a combination product comprising ZD6474 and a taxane for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and a taxane; to the use of ZD6474 and a taxane in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal, which comprises administering to said animal an effective amount of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (ZD64741 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of a taxane selected from the group consisting of paclitaxel and docetaxel.

### Claim at position 3

3-14. (canceled)

### Claim 15

A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal, which comprises administering to said animal an effective amount of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (ZD6474) or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of a taxane selected from the group consisting of paclitaxel and docetaxel; where the cancer involving a solid tumour is selected from cancer of the colon, breast, prostate, lungs, and skin.

### Claim 16 (depends on 15)

The method according to claim 15 wherein the cancer involving a solid tumour is selected from cancer of the colon, breast and lungs.
